Furthermore, in vitro experiments have demonstrated the effectiveness of combining HDAC inhibitors and antiandrogen therapy in inhibiting prostate cancer cell viability, supporting the synergistic interaction between these agents. The gene discussed is HDAC9; the disease is prostate cancer.